Skip to main content
Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
14.18
-0.80 (-5.34%)
At close: Feb 21, 2025, 4:00 PM
14.29
+0.11 (0.78%)
After-hours: Feb 21, 2025, 7:30 PM EST

Myriad Genetics Revenue

Myriad Genetics had revenue of $213.30M in the quarter ending September 30, 2024, with 11.15% growth. This brings the company's revenue in the last twelve months to $823.60M, up 12.15% year-over-year. In the year 2023, Myriad Genetics had annual revenue of $753.20M with 11.03% growth.

Revenue (ttm)
$823.60M
Revenue Growth
+12.15%
P/S Ratio
1.54
Revenue / Employee
$305,037
Employees
2,700
Market Cap
1.29B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023753.20M74.80M11.03%
Dec 31, 2022678.40M-12.20M-1.77%
Dec 31, 2021690.60M133.60M23.99%
Dec 31, 2020557.00M-81.60M-12.78%
Jun 30, 2020638.60M-212.50M-24.97%
Jun 30, 2019 Pro Pro Pro
Jun 30, 2018 Pro Pro Pro
Jun 30, 2017 Pro Pro Pro
Jun 30, 2016 Pro Pro Pro
Jun 30, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 400.28B
Johnson & Johnson 88.82B
Merck & Co. 64.17B
AbbVie 56.33B
AstraZeneca 54.07B
Novartis AG 51.72B
Eli Lilly and Company 45.04B
Thermo Fisher Scientific 42.88B
Revenue Rankings

MYGN News

More News